JPH10265321A - Skin preparation for external use - Google Patents
Skin preparation for external useInfo
- Publication number
- JPH10265321A JPH10265321A JP9085747A JP8574797A JPH10265321A JP H10265321 A JPH10265321 A JP H10265321A JP 9085747 A JP9085747 A JP 9085747A JP 8574797 A JP8574797 A JP 8574797A JP H10265321 A JPH10265321 A JP H10265321A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- extract
- tranexamic acid
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 230000002087 whitening effect Effects 0.000 claims abstract description 26
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 24
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 23
- 239000000419 plant extract Substances 0.000 claims abstract description 11
- 241001116389 Aloe Species 0.000 claims abstract description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 3
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 3
- 235000018185 Betula X alpestris Nutrition 0.000 claims abstract 3
- 235000018212 Betula X uliginosa Nutrition 0.000 claims abstract 3
- 239000000284 extract Substances 0.000 claims description 9
- 239000012676 herbal extract Substances 0.000 claims description 7
- 244000018633 Prunus armeniaca Species 0.000 claims description 3
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 3
- 241001529742 Rosmarinus Species 0.000 claims description 3
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 241000252229 Carassius auratus Species 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- 244000124209 Crocus sativus Species 0.000 claims description 2
- 235000015655 Crocus sativus Nutrition 0.000 claims description 2
- 241000544061 Cuculus canorus Species 0.000 claims description 2
- 235000002767 Daucus carota Nutrition 0.000 claims description 2
- 244000000626 Daucus carota Species 0.000 claims description 2
- 241000195955 Equisetum hyemale Species 0.000 claims description 2
- 235000011201 Ginkgo Nutrition 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 240000000599 Lentinula edodes Species 0.000 claims description 2
- 241000736199 Paeonia Species 0.000 claims description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 235000004347 Perilla Nutrition 0.000 claims description 2
- 244000124853 Perilla frutescens Species 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 235000017276 Salvia Nutrition 0.000 claims description 2
- 244000273928 Zingiber officinale Species 0.000 claims description 2
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 2
- 235000008397 ginger Nutrition 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 235000013974 saffron Nutrition 0.000 claims description 2
- 239000004248 saffron Substances 0.000 claims description 2
- 244000235603 Acacia catechu Species 0.000 claims 1
- 235000006020 Acacia catechu Nutrition 0.000 claims 1
- 241000272201 Columbiformes Species 0.000 claims 1
- 240000008397 Ganoderma lucidum Species 0.000 claims 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims 1
- 235000014435 Mentha Nutrition 0.000 claims 1
- 241001072983 Mentha Species 0.000 claims 1
- 240000007164 Salvia officinalis Species 0.000 claims 1
- 244000223014 Syzygium aromaticum Species 0.000 claims 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims 1
- 239000001560 acacia catechu Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 abstract description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 abstract description 4
- 150000002148 esters Chemical class 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 244000288377 Saxifraga stolonifera Species 0.000 abstract description 2
- 235000002953 Saxifraga stolonifera Nutrition 0.000 abstract description 2
- 150000001408 amides Chemical class 0.000 abstract description 2
- 229960005219 gentisic acid Drugs 0.000 abstract description 2
- 235000001553 Betula platyphylla Nutrition 0.000 abstract 1
- 241001313086 Betula platyphylla Species 0.000 abstract 1
- 244000184734 Pyrus japonica Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 244000081822 Uncaria gambir Species 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 27
- 239000012071 phase Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- -1 Polyoxyethylene Polymers 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FERWBXLFSBWTDE-UHFFFAOYSA-N 3-aminobutan-2-ol Chemical compound CC(N)C(C)O FERWBXLFSBWTDE-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- JBRMEFWJFBHUKG-UHFFFAOYSA-N 4-[(diaminomethylideneamino)methyl]cyclohexane-1-carboxylic acid Chemical compound NC(N)=NCC1CCC(C(O)=O)CC1 JBRMEFWJFBHUKG-UHFFFAOYSA-N 0.000 description 1
- XHPXSMWMAJGYBS-UHFFFAOYSA-N 4-[[(4-carboxycyclohexyl)methylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CNCC1CCC(C(O)=O)CC1 XHPXSMWMAJGYBS-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- UEQVLKWMHAYVLO-MGCOHNPYSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O UEQVLKWMHAYVLO-MGCOHNPYSA-N 0.000 description 1
- IFYATEIGOYKKKS-KYZUINATSA-N CC(=O)NC[C@H]1CC[C@H](C(O)=O)CC1 Chemical compound CC(=O)NC[C@H]1CC[C@H](C(O)=O)CC1 IFYATEIGOYKKKS-KYZUINATSA-N 0.000 description 1
- AVWTXYWHGFHGQD-ZKCHVHJHSA-N CNC(=O)[C@H]1CC[C@H](CN)CC1 Chemical compound CNC(=O)[C@H]1CC[C@H](CN)CC1 AVWTXYWHGFHGQD-ZKCHVHJHSA-N 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は皮膚美白効果が著しく改
良された安全性の高い皮膚外用剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a highly safe external preparation for skin which has significantly improved skin whitening effect.
【0002】[0002]
【従来の技術】皮膚のしみ、そばかすなどの色素沈着
は、ホルモンの異常や紫外線の刺激がきっかけとなっ
て、表皮色素細胞内でのメラニン産生が亢進し、メラニ
ンが表皮に過剰に沈着するため生ずる。しみ、そばかす
を防ぐにはメラニンの生成を抑制する物質であるトラネ
キサム酸を軟膏、クリーム、ローションなどの形態にし
て、局所に塗布するとの報告がある。2. Description of the Related Art Pigments such as skin spots and freckles are stimulated by abnormal hormones and ultraviolet rays, resulting in increased production of melanin in epidermal pigment cells and excessive deposition of melanin on the epidermis. Occurs. To prevent spots and freckles, it has been reported that tranexamic acid, a substance that suppresses the production of melanin, is applied topically in the form of an ointment, cream, lotion or the like.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、トラネ
キサム酸の期待される効果は未だ満足のいくものではな
かった。本発明はトラネキサム酸のもつ美白作用を高
め、実用的に十分な美白効果を有する皮膚外用剤を提供
することを課題とした。However, the expected effects of tranexamic acid have not yet been satisfactory. An object of the present invention is to provide a skin external preparation which enhances the whitening effect of tranexamic acid and has a practically sufficient whitening effect.
【0004】[0004]
【課題を解決するための手段】本発明者等は、このよう
な事情に鑑み、真に優れた美白効果を有する皮膚外用剤
を得るべく鋭意研究を重ねた結果、トラネキサム酸およ
びその誘導体よりなる群から選ばれた一種または二種以
上と、美白作用を有する植物抽出物または生薬エキスを
少なくとも一つ併用することにより相乗的な美白効果が
得られることを見出し、本発明を完成するに至った。す
なわち、本発明の請求項1はトラネキサム酸およびその
誘導体から選ばれた一種または二種以上と、美白作用を
有する植物抽出物または生薬エキスを少なくとも一つ含
有することを特徴とする皮膚外用剤である。In view of such circumstances, the present inventors have conducted intensive studies to obtain a skin external preparation having a truly excellent whitening effect. As a result, the present inventors have found that tranexamic acid and derivatives thereof are obtained. One or more selected from the group, and found that a synergistic whitening effect can be obtained by using at least one plant extract or crude drug extract having a whitening effect, and completed the present invention. . That is, claim 1 of the present invention is a skin external preparation characterized by containing one or more selected from tranexamic acid and derivatives thereof and at least one plant extract or crude drug extract having a whitening effect. is there.
【0005】本発明の請求項2は、請求項1記載の皮膚
外用剤中の美白作用を有する植物抽出物または生薬エキ
スが、アセンヤク、カミツレ、アロエ、オウゴン、ユキ
ノシタ、クララ、クジン、シラカバ、バーチ、オウバ
ク、シコン、エンメイソウ、エイジツ、ローズマリー、
サルビア、ショウキョウ、マロニエ、シソ、コラデカバ
ロ、ルムプヤン、カノコソウ、カッコン、カンゾウ、シ
イタケ、ニンジン、レイシ、コメヌカ、センキュウ、モ
モ、イチョウ、センブリ、アンズ、サフラン、ハッカ、
キョウニン、キンギンカ、ボタンピ、スギナ、カイソ
ウ、シャクヤク、チョウジ、ハマメリスまたはこれらの
エキスのうち少なくとも一つであることを特徴とする皮
膚外用剤である。[0005] In a second aspect of the present invention, the plant extract or herbal extract having a whitening effect in the external preparation for skin according to the first aspect is characterized in that the extract is Asenyaku, Chamomile, Aloe, Ogon, Yukinoshita, Clara, Kujin, Birch, Birch. , Oak, sicon, emisoso, age, rosemary,
Salvia, ginger, marronnier, perilla, koradekabaro, lumpuyan, kanokoso, cuckoo, licorice, shiitake, carrot, litchi, komenuka, senkyu, peach, ginkgo, senburi, apricot, saffron, mint,
An external preparation for skin characterized by being at least one of kyonin, goldfish, buttonpig, horsetail, gypsophila, peonies, butterflies, hamamelis or an extract thereof.
【0006】本発明の請求項3は、請求項1または2記
載の皮膚外用剤中の美白作用を有する植物抽出物または
生薬エキスの配合量が皮膚外用剤全量中、0.001〜
20重量%であることを特徴とする皮膚外用剤である。
本発明の請求項4は、請求項1〜3記載の皮膚外用剤中
のトラネキサム酸およびその誘導体の一種または二種以
上の配合量が皮膚外用剤全量中、0. 001〜20重量
%であることを特徴とする皮膚外用剤である。In a third aspect of the present invention, the amount of the plant extract or herbal extract having a whitening effect in the external preparation for skin according to the first or second aspect is 0.001 to 0.001 of the total amount of the external preparation for skin.
20% by weight of a skin external preparation.
According to a fourth aspect of the present invention, the amount of one or more tranexamic acids and derivatives thereof in the external preparation for skin according to the first to third aspects is 0.001 to 20% by weight based on the total amount of the external preparation for skin. An external preparation for skin, characterized in that:
【0007】以下、本発明の構成について詳述する。本
発明で使用するトラネキサム酸は、メラニン産生の律速
段階であるチロシナーゼ反応に対して抑制作用を示す。
本発明で使用するトラネキサム酸の誘導体としては、ト
ラネキサム酸の二量体(塩酸トランス−4−(トランス
−4−アミノメチルシクロヘキサンカルボニル)アミノ
メチルシクロヘキサンカルボン酸)、トラネキサム酸と
ハイドロキノンのエステル体(トランス−4−アミノメ
チルシクロヘキサンカルボン酸4’−ヒドロキシフェニ
ルエステル)、トラネキサム酸とゲンチシン酸のエステ
ル体(2−(トランス−4−アミノメチルシクロヘキシ
ルカルボニルオキシ)−5−ヒドロキシ安息香酸および
その塩)、トラネキサム酸のアミド体(トランス−4−
アミノメチルシクロヘキサンカルボン酸メチルアミドお
よびその塩、トランス−4−アセチルアミノメチルシク
ロヘキサンカルボン酸およびその塩、トランス−4−
(p−メトキシベンゾイル)アミノメチルシクロヘキサ
ンカルボン酸およびその塩、トランス−4−グアニジノ
メチルシクロヘキサンカルボン酸およびその塩等)等が
挙げられる。Hereinafter, the configuration of the present invention will be described in detail. Tranexamic acid used in the present invention has an inhibitory effect on the tyrosinase reaction, which is the rate-limiting step of melanin production.
Examples of the tranexamic acid derivative used in the present invention include a tranexamic acid dimer (trans-4- (trans-4-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid hydrochloride) and an ester form of tranexamic acid and hydroquinone (trans 4-aminomethylcyclohexanecarboxylic acid 4'-hydroxyphenyl ester), an ester form of tranexamic acid and gentisic acid (2- (trans-4-aminomethylcyclohexylcarbonyloxy) -5-hydroxybenzoic acid and a salt thereof), tranexam Amide of acid (trans-4-
Aminomethylcyclohexanecarboxylic acid methylamide and salts thereof, trans-4-acetylaminomethylcyclohexanecarboxylic acid and salts thereof, trans-4-
(P-methoxybenzoyl) aminomethylcyclohexanecarboxylic acid and salts thereof, trans-4-guanidinomethylcyclohexanecarboxylic acid and salts thereof, and the like.
【0008】本発明に係る皮膚外用剤に配合されるトラ
ネキサム酸およびその誘導体から選ばれた一種または二
種以上の配合量には特に限定はないが、一般には皮膚外
用剤全量に対して0.001〜20重量%、好ましくは
0.01〜10重量%、特に好ましくは0.1〜7重量
%配合する。この配合量が0.001重量%未満では皮
膚外用剤の美白効果が乏しくなる傾向にあり、逆に、2
0重量%を超えて配合しても効果の増加は実質上望めな
いし、皮膚外用剤への配合も難しくなる傾向にある。The amount of one or more selected from tranexamic acid and its derivatives to be incorporated in the external preparation for skin according to the present invention is not particularly limited. 001 to 20% by weight, preferably 0.01 to 10% by weight, particularly preferably 0.1 to 7% by weight. If the amount is less than 0.001% by weight, the skin whitening effect of the external preparation tends to be poor.
Even if it is added in excess of 0% by weight, an increase in the effect cannot be substantially expected, and it tends to be difficult to incorporate it into an external preparation for skin.
【0009】本発明に係る皮膚外用剤に配合される美白
作用を有する植物抽出物または生薬エキスは、美白作用
を有するものであればよい。[0009] The plant extract or herbal extract having a whitening effect to be incorporated in the external preparation for skin according to the present invention may be any one having a whitening effect.
【0010】美白作用を有する植物抽出物または生薬エ
キスの配合量には特に限定はないが、一般には、皮膚外
用剤全量に対して0.001〜20重量%、好ましくは
0.1〜5重量%配合する。この配合量が0.001重
量%未満では皮膚外用剤の美白効果および皮膚外用剤の
皮膚刺激性を抑制する効果が乏しくなる傾向にあり、逆
に、20重量%を超えて配合しても効果の増加は実質上
望めないし、皮膚外用剤への配合も難しくなる傾向にあ
る。The amount of the plant extract or herbal extract having a whitening effect is not particularly limited, but is generally 0.001 to 20% by weight, preferably 0.1 to 5% by weight, based on the total amount of the external preparation for skin. %. When the amount is less than 0.001% by weight, the skin whitening effect of the external preparation for skin and the effect of suppressing the skin irritation of the external preparation tend to be poor. Is substantially not expected, and it tends to be difficult to incorporate into skin external preparations.
【0011】本発明の皮膚外用剤には上記した必須成分
の他に通常化粧品や医薬品等の皮膚外用剤に用いられる
他の成分例えば油分、湿潤剤、紫外線吸収剤、酸化防止
剤、界面活性剤、防腐剤、保湿剤、香料、水、アルコー
ル、増粘剤等を必要に応じて適宜配合することができ
る。本発明に係る皮膚外用剤の剤型は任意であり例えば
化粧水などの可溶化系、乳液、クリームなどの乳化系、
又は軟膏、分散液などの任意の剤型をとることができ
る。The external preparation for skin of the present invention contains, in addition to the above essential components, other components usually used in external preparations for skin such as cosmetics and pharmaceuticals, such as oils, wetting agents, ultraviolet absorbers, antioxidants, and surfactants. , A preservative, a humectant, a fragrance, water, alcohol, a thickener and the like can be appropriately compounded as required. The dosage form of the external preparation for skin according to the present invention is arbitrary and, for example, a solubilizing system such as a lotion, an emulsion, an emulsifying system such as a cream,
Alternatively, any dosage form such as an ointment and a dispersion can be used.
【0012】[0012]
【実施例】次に実施例をあげて本発明を更に詳しく説明
するが、本発明の技術的範囲をこれらの実施例に限定す
るものでないことはいうまでもない。なお、以下の実施
例において配合量は重量%である。The present invention will be described in more detail with reference to the following examples, but it goes without saying that the technical scope of the present invention is not limited to these examples. In addition, in the following examples, the compounding amount is% by weight.
【0013】まず、実施例に先立ち効果試験方法および
評価方法について説明する。美白効果は、累積塗布によ
る皮膚に対する色白効果、しみ、そばかすの解消などの
使用テストから判定した。First, an effect test method and an evaluation method will be described prior to Examples. The whitening effect was determined from use tests such as the skin whitening effect by cumulative application, the removal of spots and freckles, and the like.
【0014】(1)美白効果 (試験方法)色黒、しみ、そばかす等に悩む、被試験
者、1群20名として、1つの試料ローションを朝夕、
3ケ月間、毎日顔面に塗布し、3ケ月後にその美白効果
を調べた。下記に示す処方で実施例1〜7、比較例1〜
8について試験を行った。 実施例1〜7、比較例1〜8の試料 (アルコ−ル相) 重量% 95%エタノール 25.0 ポリオキシエチレン(25モル)硬化ヒマシ油エーテル 2.0 防腐剤・酸化防止剤 適 量 香料 適 量 薬剤(表1記載) (水相) グリセリン 2.0 プロピレングリコール 1.0 イオン交換水 残 余 (製法)水相、アルコール相を調製後可溶化する。(1) Whitening effect (Testing method) A subject suffering from darkness, spots, freckles, etc., one sample lotion in the morning and evening
It was applied to the face every day for 3 months and its whitening effect was examined after 3 months. Examples 1 to 7 and Comparative Examples 1 to 7 with the following formulation
8 were tested. Samples of Examples 1 to 7 and Comparative Examples 1 to 8 (alcohol phase)% by weight 95% Ethanol 25.0 Polyoxyethylene (25 mol) hydrogenated castor oil ether 2.0 Preservative / Antioxidant Appropriate amount Fragrance Appropriate amount Drug (described in Table 1) (Aqueous phase) Glycerin 2.0 Propylene glycol 1.0 Ion-exchanged water Residue (Preparation method) Prepare aqueous phase and alcohol phase and solubilize.
【0015】[0015]
【表1】 [Table 1]
【0016】(判定基準) 著 効:色素沈着がほとんど目立たなくなった。 有 効;非常にうすくなった。 やや有効:ややうすくなった。 無 効:変化無し (判定) ◎:被試験者のうち著効、有効の示す割合(有効率)が
80%以上の場合 ○:被試験者のうち著効、有効の示す割合(有効率)が
50%以上80%未満の場合 △:被試験者のうち著効、有効の示す割合(有効率)が
30%以上50%未満の場合 ×:被試験者のうち著効、有効の示す割合(有効率)が
30%未満の場合(Evaluation Criteria) Significant Effect: Pigmentation became almost inconspicuous. Effective; very thin. Somewhat effective: Somewhat thin. Ineffective: no change (judgment) ◎: The proportion of the test subjects showing significant efficacy and effectiveness (effective rate) is 80% or more ○: The proportion of the test subjects showing significant efficacy and efficacy (effective rate) Is greater than or equal to 50% and less than 80% Δ: The proportion of effective and effective among testees (effective rate) is 30% or more and less than 50% ×: The proportion of excellent and effective among examinees (Effective rate) is less than 30%
【0017】[0017]
【表2】 [Table 2]
【0018】表2より明らかなように、比較例に比べ
て、実施例の方が優れた皮膚美白効果を有することが認
められた。As is evident from Table 2, it was recognized that the Examples had a better skin whitening effect than the Comparative Examples.
【0019】 実施例8 バニシングクリーム ステアリン酸 6.0 ソルビタンモノステアリン酸エステル 2.0 ポリオキシエチレン(20モル) ソルビタンモノステアリン酸エステル 1.5 トラネキサム酸 2.0 プロピレングルコール 10.0 エンメイソウ抽出物 5.0 防腐剤・酸化防止剤 適 量 香料 適 量 イオン交換水 残 余 (製法)イオン交換水にエンメイソウ、トラネキサム酸
及びプロピレングリコールを加え加熱して70℃に保つ
(水相)。他の成分を混合し加熱融解して70℃に保つ
(油相)。水相に油相を加え予備乳化を行い、ホモミキ
サーで均一に乳化した後、よくかきまぜながら、30℃
まで冷却する。Example 8 Vanishing cream stearic acid 6.0 sorbitan monostearate 2.0 polyoxyethylene (20 mol) sorbitan monostearate 1.5 tranexamic acid 2.0 propylene glycol 10.0 5.0 Preservative / Antioxidant Appropriate amount Fragrance Appropriate amount Ion-exchanged water residue (Preparation method) Add enmeiso, tranexamic acid and propylene glycol to ion-exchanged water and heat to 70 ° C (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). Add oil phase to water phase, pre-emulsify and homogenize with homomixer.
Cool down to
【0020】 実施例9 中性クリーム ステアリルアルコール 7.0 ステアリン酸 2.0 水添ラノリン 2.0 スクワラン 5.0 2−オクチルドデシリアルコール 6.0 ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0 グリセリンモノステアリン酸エステル 2.0 胎盤抽出物 0.1 トラネキサム酸 1.0 パラメトキシ桂皮酸2−エチルヘキシル 2.5 プロピレングリコール 5.0 カンゾウ抽出物 10.0 香料 適 量 防腐剤・酸化防止剤 適 量 イオン交換水 残 余 (製法)イオン交換水にカンゾウ抽出物、胎盤抽出物、
トラネキサム酸及びプロピレングリコールを加え加熱し
て70℃に保つ(水相)。他の成分を混合し加熱融解し
て70℃に保つ(油相)。水相に油相を加え予備乳化を
行い、ホモミキサーで均一に乳化した後、よくかきまぜ
ながら、30℃まで冷却する。Example 9 Neutral Cream Stearyl Alcohol 7.0 Stearic Acid 2.0 Hydrogenated Lanolin 2.0 Squalane 5.0 2-Octyldo Deserial Call 6.0 Polyoxyethylene (25 mol) Cetyl Alcohol Ether 3 2.0 Glycerin monostearate 2.0 Placenta extract 0.1 Tranexamic acid 1.0 2-Ethylhexyl paramethoxycinnamate 2.5 Propylene glycol 5.0 Licorice extract 10.0 Perfume Appropriate preservative / antioxidant Appropriate amount Ion-exchanged water residue (Preparation method) Addition of licorice extract, placenta extract,
Add tranexamic acid and propylene glycol and heat to maintain at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the water phase to perform preliminary emulsification, and after uniform emulsification with a homomixer, the mixture is cooled to 30 ° C. while stirring well.
【0021】 実施例10 コールドクリーム 固型パラフィン 5.0 蜜ロウ 10.0 ワセリン 15.0 流動パラフィン 41.0 グリセリンモノステアリン酸エステル 2.0 ポリオキシエチレン(20モル) ソルビタンモノラウリン酸エステル 2.0 トラネキサム酸 4.0 石鹸粉末 0.1 硼砂 0.2 カミツレ抽出物 0.1 イオン交換水 残 余 香料 適 量 防腐剤・酸化防止剤 適 量 (製法)イオン交換水にカミツレ抽出物、トラネキサム
酸、石鹸粉末および硼砂を加え加熱溶解して70℃に保
つ(水相)。他の成分を混合し加熱融解して70℃に保
つ(油相)。水相に油相をかきまぜながら徐々の加え反
応を行う。反応終了後ホモミキサーで均一に乳化し、乳
化後よくかきまぜながら30℃まで冷却する。Example 10 Cold cream Solid paraffin 5.0 Beeswax 10.0 Vaseline 15.0 Liquid paraffin 41.0 Glycerin monostearate 2.0 Polyoxyethylene (20 mol) Sorbitan monolaurate 2.0 Tranexamic acid 4.0 Soap powder 0.1 Borax 0.2 Chamomile extract 0.1 Ion-exchanged water Residual perfume Appropriate amount Preservative / antioxidant Appropriate amount (Production method) Chamomile extract, ionized water, tranexamic acid, Soap powder and borax are added and dissolved by heating, and kept at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is gradually added to the aqueous phase while stirring to carry out the reaction. After the completion of the reaction, the mixture is uniformly emulsified with a homomixer, and cooled to 30 ° C. while stirring well after emulsification.
【0022】 実施例11 乳 液 ポリオキシエチレン(20モル) ポリオキシプロピレン(2モル)セチルアルコール 1.0 シリコーンKF96(20cs)(信越化学) 2.0 流動パラフィン(中粘度) 3.0 プロピレングリコール 5.0 トラネキサム酸 2.0 グリセリン 2.0 エタノール 15.0 カルボキシビニルポリマー 0.3 ヒドロキシプロピルセルロース 0.1 2−アミノメチルプロパノール 0.1 防腐剤 適 量 アロエ抽出物 20.0 イオン交換水 残 余 (製法)イオン交換水とエタノールにアロエ抽出物の含
水アルコール抽出物及びトラネキサム酸 を加温溶解
し、更にプロピレングリコール以下の水溶性成分を溶解
して、70℃に保つ(水相)。他の油性成分を混合し、
加熱融解して70℃に保つ(油相)。水相に油相を加
え、予備乳化を行い、ホモミキサーで均一乳化し、乳化
後、よくかきまぜながら、30℃まで冷却する。Example 11 Emulsion Polyoxyethylene (20 mol) Polyoxypropylene (2 mol) Cetyl alcohol 1.0 Silicone KF96 (20 cs) (Shin-Etsu Chemical) 2.0 Liquid paraffin (medium viscosity) 3.0 Propylene glycol 5.0 Tranexamic acid 2.0 Glycerin 2.0 Ethanol 15.0 Carboxyvinyl polymer 0.3 Hydroxypropylcellulose 0.1 2-Aminomethylpropanol 0.1 Preservative Appropriate amount Aloe extract 20.0 Deionized water residue (Preparation method) The aqueous alcohol extract of the aloe extract and tranexamic acid are dissolved by heating in ion-exchanged water and ethanol, and the water-soluble components such as propylene glycol are dissolved, and the mixture is kept at 70 ° C. (aqueous phase). Mix with other oily ingredients,
Heat to melt and maintain at 70 ° C (oil phase). The oil phase is added to the water phase, preliminarily emulsified, homogenized with a homomixer, emulsified, and cooled to 30 ° C. while stirring well.
【0023】 実施例12 乳 液 ポリオキシエチレン(20モル) ポリオキシプロピレン(2モル)セチルアルコール 1.0 シリコーンKF96(20cs)(信越化学) 2.0 流動パラフィン(中粘度) 3.0 プロピレングリコール 5.0 アスコルビン酸−2−グルコシド 5.0 トラネキサム酸 5. 5 tert−ブチル−4’−メトキシベンゾイルメタン 3. 0 グリセリン 2.0 エタノール 15.0 カルボキシビニルポリマー 0.3 ヒドロキシプロピルセルロース 0.1 2−アミノメチルプロパノール 0.1 防腐剤 適 量 マロニエ抽出物 7.0 イオン交換水 残 余 (製法)イオン交換水とエタノールにマロニエ抽出物、
トラネキサム酸を加温溶解し、更にプロピレングリコー
ル以下の水溶性成分を溶解して、70℃に保つ(水
相)。他の油性成分を混合し、加熱融解して70℃に保
つ(油相)。水相に油相を加え、予備乳化を行い、ホモ
ミキサーで均一に乳化し、乳化後、よくかきまぜなが
ら、30℃まで冷却する。Example 12 Emulsion Polyoxyethylene (20 mol) Polyoxypropylene (2 mol) Cetyl alcohol 1.0 Silicone KF96 (20cs) (Shin-Etsu Chemical) 2.0 Liquid paraffin (medium viscosity) 3.0 Propylene glycol 5.0 Ascorbic acid-2-glucoside 5.0 Tranexamic acid 5.5 tert-butyl-4'-methoxybenzoylmethane 3.0 Glycerin 2.0 Ethanol 15.0 Carboxyvinyl polymer 0.3 Hydroxypropylcellulose 0.1 2-Aminomethylpropanol 0.1 Preservative Appropriate amount Marronnier extract 7.0 Ion-exchanged water residue (Preparation method)
The tranexamic acid is dissolved by heating, and the water-soluble component of propylene glycol or lower is dissolved, and kept at 70 ° C. (aqueous phase). The other oil components are mixed, heated and melted and kept at 70 ° C. (oil phase). The oil phase is added to the water phase, preliminarily emulsified, and uniformly emulsified by a homomixer. After emulsification, the mixture is cooled to 30 ° C. while stirring well.
【発明の効果】本発明に係る皮膚外用剤は、皮膚美白効
果が著しく改良された安全性の高い皮膚外用剤である。The external preparation for skin according to the present invention is a highly safe external preparation for skin with significantly improved skin whitening effect.
Claims (4)
作用を有する植物抽出物または生薬エキスとを含有する
ことを特徴とする皮膚外用剤。1. An external preparation for skin, comprising tranexamic acid and a derivative thereof, and a plant extract or herbal extract having a whitening effect.
作用を有する植物抽出物または生薬エキスがアセンヤ
ク、カミツレ、アロエ、オウゴン、ユキノシタ、クラ
ラ、クジン、シラカバ、バーチ、オウバク、シコン、エ
ンメイソウ、エイジツ、ローズマリー、サルビア、ショ
ウキョウ、マロニエ、シソ、コラデカバロ、ルムプヤ
ン、カノコソウ、カッコン、カンゾウ、シイタケ、ニン
ジン、レイシ、コメヌカ、センキュウ、モモ、イチョ
ウ、センブリ、アンズ、サフラン、ハッカ、キョウニ
ン、キンギンカ、ボタンピ、スギナ、カイソウ、シャク
ヤク、チョウジ、ハマメリスまたはこれらのエキスのう
ち少なくとも一つであることを特徴とする皮膚外用剤。2. The external preparation for skin according to claim 1, wherein the plant extract or herbal extract having a whitening effect is acacia catechu, chamomile, aloe, ogon, yukinosita, clara, kujin, birch, birch, oakaku, sicon, emmeiso, Ages, rosemary, salvia, ginger, marronnier, perilla, koradekabaro, rumpuyan, kanokoso, cuckoo, licorice, shiitake mushroom, carrot, reishi, komenuka, senkyu, peach, ginkgo, apricot, apricot, saffron, mentha, kyonin, goldfish An external preparation for skin, characterized by being at least one of buttoned pigeon, horsetail, diatom, peonies, clove, hammeris or an extract thereof.
て、美白作用を有する植物抽出物または生薬エキスの配
合量が皮膚外用剤全量中、0.001〜20重量%であ
ることを特徴とする皮膚外用剤。3. The external preparation for skin according to claim 1 or 2, wherein the amount of the plant extract or herbal extract having a whitening effect is 0.001 to 20% by weight based on the total amount of the external preparation for skin. External preparation for skin.
トラネキサム酸およびその誘導体の一種または二種以上
の配合量が皮膚外用剤全量中、0. 001〜20重量%
であることを特徴とする皮膚外用剤。4. The external preparation for skin according to claim 1, wherein
One or more of tranexamic acid and its derivatives are contained in an amount of 0.001 to 20% by weight based on the total amount of the external preparation for skin.
An external preparation for skin, characterized in that:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9085747A JPH10265321A (en) | 1997-03-19 | 1997-03-19 | Skin preparation for external use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9085747A JPH10265321A (en) | 1997-03-19 | 1997-03-19 | Skin preparation for external use |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10265321A true JPH10265321A (en) | 1998-10-06 |
Family
ID=13867452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9085747A Withdrawn JPH10265321A (en) | 1997-03-19 | 1997-03-19 | Skin preparation for external use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10265321A (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11302125A (en) * | 1998-04-24 | 1999-11-02 | Shiseido Co Ltd | Whitening cosmetic |
JP2000007544A (en) * | 1998-06-16 | 2000-01-11 | Matsukawa Kagaku:Kk | Cosmetic |
JP2000143479A (en) * | 1998-11-05 | 2000-05-23 | Kao Corp | Whitening cosmetics |
JP2000302661A (en) * | 1999-04-21 | 2000-10-31 | Kao Corp | Cosmetics |
JP2001031558A (en) * | 1999-05-19 | 2001-02-06 | Kose Corp | Skin lotion |
JP2001031580A (en) * | 1999-05-19 | 2001-02-06 | Kose Corp | Preparation for external use for skin |
US6214352B1 (en) | 2000-01-06 | 2001-04-10 | Matsukawa Kagaku Co., Ltd. | Tyrosinase inhibiting agent |
JP2002003358A (en) * | 2000-06-23 | 2002-01-09 | Shiseido Co Ltd | Skin care preparation |
JP2002212052A (en) * | 2001-01-15 | 2002-07-31 | Hajime Ito | External preparation |
JP2002284626A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | External skin preparation |
JP2002284625A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
JP2003160461A (en) * | 2001-11-21 | 2003-06-03 | Shiseido Co Ltd | Skin care preparation |
JP2003192531A (en) * | 2002-02-28 | 2003-07-09 | Noevir Co Ltd | Skin care preparation aiming at increase of scattered light on skin surface |
JP2004083476A (en) * | 2002-08-27 | 2004-03-18 | Horin:Kk | Tyrosinase inhibitor, demelanizing agent, fibroblast reproductive factor and estrogenic substance, and skin cosmetic |
JP2005015450A (en) * | 2003-06-30 | 2005-01-20 | Kanebo Cosmetics Inc | Skin cosmetics |
JP2005023042A (en) * | 2003-07-04 | 2005-01-27 | Noevir Co Ltd | External preparation for skin |
JP2005104938A (en) * | 2003-10-02 | 2005-04-21 | Matsukawa Kagaku:Kk | Skin cosmetic |
KR100504408B1 (en) * | 2002-10-29 | 2005-07-27 | 주식회사 코리아나화장품 | Cosmetic Composition for Skin-Whitening Comprising Senkyunolide A as Active Ingredient |
JP2008100933A (en) * | 2006-10-18 | 2008-05-01 | Daiichi Sankyo Healthcare Co Ltd | External preparation for skin |
JP2011195495A (en) * | 2010-03-19 | 2011-10-06 | Pola Chemical Industries Inc | Composition |
JP2011219403A (en) * | 2010-04-08 | 2011-11-04 | Pola Chemical Industries Inc | Cell activator |
JP2011241164A (en) * | 2010-05-18 | 2011-12-01 | Pola Chemical Industries Inc | Composition |
JP2013014633A (en) * | 2012-10-24 | 2013-01-24 | Daiichi Sankyo Healthcare Co Ltd | Skin care preparation for external use |
JP2013126980A (en) * | 2011-12-19 | 2013-06-27 | Amorepacific Corp | Cosmetic composition for antioxidation or skin-whitening containing mixed extract of korean drug material |
JP2015117196A (en) * | 2013-12-18 | 2015-06-25 | 花王株式会社 | Whitening cosmetics |
US9227090B2 (en) | 2008-06-18 | 2016-01-05 | Conopco, Inc. | Method for lightening skin |
JP2017178821A (en) * | 2016-03-29 | 2017-10-05 | ポーラ化成工業株式会社 | Peroxiredoxin expression enhancer |
JPWO2020179587A1 (en) * | 2019-03-04 | 2020-09-10 | ||
WO2020204191A1 (en) | 2019-04-05 | 2020-10-08 | 株式会社 資生堂 | Cosmetic containing ultraviolet wavelength conversion substance and medicinal agent |
-
1997
- 1997-03-19 JP JP9085747A patent/JPH10265321A/en not_active Withdrawn
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11302125A (en) * | 1998-04-24 | 1999-11-02 | Shiseido Co Ltd | Whitening cosmetic |
JP2000007544A (en) * | 1998-06-16 | 2000-01-11 | Matsukawa Kagaku:Kk | Cosmetic |
JP2000143479A (en) * | 1998-11-05 | 2000-05-23 | Kao Corp | Whitening cosmetics |
JP2000302661A (en) * | 1999-04-21 | 2000-10-31 | Kao Corp | Cosmetics |
JP2001031558A (en) * | 1999-05-19 | 2001-02-06 | Kose Corp | Skin lotion |
JP2001031580A (en) * | 1999-05-19 | 2001-02-06 | Kose Corp | Preparation for external use for skin |
US6214352B1 (en) | 2000-01-06 | 2001-04-10 | Matsukawa Kagaku Co., Ltd. | Tyrosinase inhibiting agent |
JP2002003358A (en) * | 2000-06-23 | 2002-01-09 | Shiseido Co Ltd | Skin care preparation |
JP2002212052A (en) * | 2001-01-15 | 2002-07-31 | Hajime Ito | External preparation |
JP2002284626A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | External skin preparation |
JP2002284625A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
JP2003160461A (en) * | 2001-11-21 | 2003-06-03 | Shiseido Co Ltd | Skin care preparation |
JP2003192531A (en) * | 2002-02-28 | 2003-07-09 | Noevir Co Ltd | Skin care preparation aiming at increase of scattered light on skin surface |
JP2004083476A (en) * | 2002-08-27 | 2004-03-18 | Horin:Kk | Tyrosinase inhibitor, demelanizing agent, fibroblast reproductive factor and estrogenic substance, and skin cosmetic |
KR100504408B1 (en) * | 2002-10-29 | 2005-07-27 | 주식회사 코리아나화장품 | Cosmetic Composition for Skin-Whitening Comprising Senkyunolide A as Active Ingredient |
JP2005015450A (en) * | 2003-06-30 | 2005-01-20 | Kanebo Cosmetics Inc | Skin cosmetics |
JP2005023042A (en) * | 2003-07-04 | 2005-01-27 | Noevir Co Ltd | External preparation for skin |
JP2005104938A (en) * | 2003-10-02 | 2005-04-21 | Matsukawa Kagaku:Kk | Skin cosmetic |
JP2008100933A (en) * | 2006-10-18 | 2008-05-01 | Daiichi Sankyo Healthcare Co Ltd | External preparation for skin |
US9227090B2 (en) | 2008-06-18 | 2016-01-05 | Conopco, Inc. | Method for lightening skin |
JP2011195495A (en) * | 2010-03-19 | 2011-10-06 | Pola Chemical Industries Inc | Composition |
JP2011219403A (en) * | 2010-04-08 | 2011-11-04 | Pola Chemical Industries Inc | Cell activator |
JP2011241164A (en) * | 2010-05-18 | 2011-12-01 | Pola Chemical Industries Inc | Composition |
JP2013126980A (en) * | 2011-12-19 | 2013-06-27 | Amorepacific Corp | Cosmetic composition for antioxidation or skin-whitening containing mixed extract of korean drug material |
JP2013014633A (en) * | 2012-10-24 | 2013-01-24 | Daiichi Sankyo Healthcare Co Ltd | Skin care preparation for external use |
JP2015117196A (en) * | 2013-12-18 | 2015-06-25 | 花王株式会社 | Whitening cosmetics |
JP2017178821A (en) * | 2016-03-29 | 2017-10-05 | ポーラ化成工業株式会社 | Peroxiredoxin expression enhancer |
JPWO2020179587A1 (en) * | 2019-03-04 | 2020-09-10 | ||
WO2020179587A1 (en) * | 2019-03-04 | 2020-09-10 | 丸善製薬株式会社 | Topical agent |
WO2020204191A1 (en) | 2019-04-05 | 2020-10-08 | 株式会社 資生堂 | Cosmetic containing ultraviolet wavelength conversion substance and medicinal agent |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10265321A (en) | Skin preparation for external use | |
JP5093998B2 (en) | Pigmentation preventing or improving agent | |
JPH10265322A (en) | Skin preparation for external use | |
JP2002284626A (en) | External skin preparation | |
JP2000016917A (en) | Skin whitening cosmetic | |
JP2021042241A (en) | Composition for external use | |
JP2005120023A (en) | Skin care preparation | |
JPH0545569B2 (en) | ||
Nualsri et al. | Development and clinical evaluation of green tea hair tonic for greasy scalp treatment | |
JP2572730B2 (en) | Skin cosmetics | |
JP2007022923A (en) | Hair follicle apoptosis reaction inhibitor and hair cosmetic composition | |
JPS6360910A (en) | Skin drug for external use | |
JP2001010926A (en) | Bleaching agent | |
JPH0196109A (en) | Skin-beautifying cosmetic | |
AU2020405222B2 (en) | Personal care compositions and methods for the same | |
JPH0620531B2 (en) | Emulsified composition | |
JPH08133950A (en) | Skin preparation for external use | |
JPH11269033A (en) | Skin treatment agent | |
JP2000119133A (en) | Skin lotion for bleaching | |
JPH03261705A (en) | Melanin production-inhibitory external agent | |
JPH0517202B2 (en) | ||
JP2000178118A (en) | Humectant, skin cosmetic and bathing agent | |
JPH11255621A (en) | Cosmetic for scalp and hair | |
JPH0692833A (en) | Skin external agent | |
JP3129358B2 (en) | Hair restorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20040601 |